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Abstract
Background: We aimed to assess whether the levels of FFAs (free fatty acids) in ACS (acute coronary syndrome)
patients depend on the extent of myocardial ischemia during the subacute phase of ACS attack.
Methods: A total of 892 consecutive CAD (coronary artery disease) subjects undergoing coronary angiography
were enrolled. The FFAs contents were measured based on enzymatic assay. The relationship between FFAs and
Gensini score and ACS susceptibility was assessed.
Results: In the overall population, the upper FFAs quartile was accompanied with higher ischemia parameters and
increased occurrence of ACS and STEMI (ST-segment elevation myocardial infarction) (P < 0.05). The FFAs
concentrations were approximately 1.5-fold higher in ACS than in stable CAD patients, roughly 1.3-fold higher in
STEMI than non-STEMI ACS patients and probably 1.3-fold higher in non-STEMI ACS than in stable CAD patients.
After adjusted for traditional cardiovascular risk factors, the FFAs level remained a risk factor for a higher Gensini
score with more than 40 (P < 0.001) and prevalent ACS (P < 0.001). After adjusted for traditional risk factors, FFAs
levels after natural logarithm transformation were associated with hs-CRP and WBC counts in ACS patients. A
multiplicative interaction was found between hs-CRP, WBC counts and FFAs in incident ACS and higher Gensini
score (P < 0.001).
Conclusions: Higher in-hospital levels of FFAs persist and may reflect the severity of ischemia and necrosis during
the subacute phase of ACS attack.
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Background
Plasma free fatty acids (FFAs) levels are elevated within
12 h after the onset of acute myocardial infarction
(AMI) [1], moreover, elevated FFAs are associated with
worse outcomes including increased risk of arrhythmia
[2], sudden cardiac death and total mortality [3]. Although
most FFAs are bound to albumin, a small fraction is un-
bound FFA (FFAu); FFAu increases in the ischemic,
under-perfused myocardium rapidly within 30 min, which
is considered to be more sensitive in physiologic changes
than bound FFAs.
Inflammation plays a critical role throughout the ath-
erosclerotic stage in various vessels, ranging from fatty
streak formation to cardiovascular events [4, 5]. Among
the potential inflammation biomarkers, C-reactive pro-
tein, the classical acute-phase protein, functions as a
highly sensitive systemic marker of inflammation and
tissue damage and can be measured by high-sensitivity
assay (hs-CRP). Numerous epidemiological studies have
demonstrated that hs-CRP had a clear prognostic
value for predicting major cardiovascular events and
mortality [6, 7].
Increased FFAu is an early predictor of ischemia in
ACS (acute coronary syndrome) [8]. Our previous study
found that plasma FFA compositions were dysregulated
in CAD (coronary artery disease) patients, partly influ-
enced by age and gene polymorphisms [9, 10]. Therefore
the objective of our study was to explore the association
between total FFAs and the severity of myocardial
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ischemia of ACS during subacute phase, and further
investigated whether this was influenced by hs-CRP.
Methods
Subjects
The study was approved by the medical ethical commit-
tee of Zhongnan Hospital of Wuhan University. All par-
ticipants were Han population from China, who gave
their informed, written consent. From 2012 to 2014, we
consecutively recruited patients who underwent selective
coronary angiography for suspected coronary atheroscler-
osis and who were admitted within 24 h from chest pain
at cardiovascular department. The diagnosis of CAD was
defined as the presence of coronary lesions ≥50 % in at
least one major artery segment assessed by two independ-
ent cardiologists who had no information of the patients’
clinical characteristics and biochemical results. We exclu-
ded all patients with additional complications including
viral hepatitis, tumor, autoimmune disease, serious liver or
renal dysfunction, myocardiopathy or valvular heart dis-
ease and patients received with heparin treatment.
Serial blood samples were taken after admission for
routine laboratory parameter tests, including liver func-
tion, kidney function, lipids and lipoproteins and myo-
cardial enzymes. Estimated glomerular filtration rate
(eGFR) was calculated using the Modification of Diet in
Renal Disease (MDRD) study equation: eGFR = 186 ×
((serumcreatinine)^(‐ 1.154)) × ((age)^(‐0.203)) × [0.742 if
female]. AMI was defined by typical clinical symptoms,
electrocardiograph changes and positive serum biomarkers
[11, 12]. Unstable angina (UA) was established based on
the criteria of Brawmwald using clinical symptoms, non-
ST segment elevation and negative serum biomarkers [13].
Assay of FFAs content
Serum samples were collected, separated and stored
at −80 °C within 24 h of admission. Samples were in-
cubated for 15 min at room temperature and then a
single determination of FFAs content was tested by
enzymatic assay (Clinimate NEFA, Tokyo, Japan).
Angiographic analysis
Catheterization and multiple views were imaged and
maximal stenosis in each coronary artery segment was
evaluated by a cardiologist according to the segmental
classification system of the Coronary Artery Surgery
Study. The extent of angiographically documented CAD
was quantified in the left anterior descending artery, the
left circumflex artery, and the right coronary artery, the
criteria were as follows: normal coronary arteries (smooth,
with either no stenosis or stenosis of <10 % of the luminal
diameter), mild coronary arteries (stenosis of 10 % to 50 %
of the luminal diameter in ≥ 1 coronary artery), or 1, 2 or
3-vessel disease, defined as stenosis of more than 50 % of
the luminal diameter.
Gensini score
To assess coronary artery disease burden based on
coronary angiogram, the Gensini score was calculated
according to Gensini scoring system [14]. The Gensini
score equaled the sum of all segment scores (where each
segment score equaled the segment weighting factor
multiplied by the severity score). Severity scores assigned
to the specific percentages of luminal diameter reduction
of the coronary artery segment were 32 for 100 %, 16 for
99 %, 8 for 90 %, 4 for 75 %, 2 for 50 %, and 1 for 5 %.
Statistical analysis
Variables were expressed as the mean ± SD, median
(25th–75th percentile) or proportions and compared
using Mann–Whitney U-test, Kruskal-Wallis H-test or
the χ2 test in univariable analysis. Binary logistic regres-
sion analysis was used to identify correlated risk factors.
All analyses were performed using PASW Statistics, ver-
sion 13.0 (SPSS, Chicago, IL, USA).
Results
Clinical characteristic
The study population consisted of 404 SCAD (stable
coronary artery disease) patients, including 294 chronic
stable angina patients (male 56.1 %, aged 68 ± 11),110
old myocardial infarction patients (male 76.4 %, aged
66 ± 12) and 488 ACS patients, including 108 UA patients
(male 56.6 %, aged 68 ± 11), 191 NSTEMI (non-ST
segment elevation myocardial infarction) patients (male
76.2 %, aged 67 ± 13) and 189 STEMI (ST segment ele-
vation myocardial infarction) patients (male 82.4 %, aged
62 ± 13).
The baseline demographic, clinical characteristics and
laboratory parameters according to the quartiles of the
FFAs levels (Q1 0.12–0.37, n = 223; Q2 0.38–0.54, n = 218;
Q3 0.55–0.78, n = 228; Q4 0.79–4.57, n = 223) for the
study population were summarized in Table 1. The distri-
bution of FFAs quartiles were slightly unbalanced with
traditional cardiovascular risk factors such as age, smok-
ing, fasting blood glucose, hs-CRP and the atherogenic
lipid parameters including TC, LDL-C, TG (P < 0.05). In
addition, the necrosis and ischemia parameters dramatic-
ally increased according to FFAs quartiles such as cTnT,
CK-MB, maximal stenosis and Gensini score (P < 0.05).
Association of FFAs with severity of ischemia and necrosis
The FFAs levels in ACS patients were higher than in
SCAD patients ((0.68 mmol/l (0.45, 0.911) vs. 0.44 mmol/l
(0.3, 0.63), P < 0.001, respectively)) (Fig. 1a), which re-
mained a significant correlation after adjustment for age
and gender (P < 0.001). Among patients with ACS, the
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higher FFAs levels remained significant between STEMI
and UA +NSTEMI patients ((0.77 mmol/l (0.55, 1.1) vs.
0.58 mmol/l (0.4, 0.83), P < 0.001, respectively)) (Fig. 1b),
which was significant after adjustment for age and gender
(P < 0.001). Meanwhile, the FFAs levels in UA +NSTEMI
patients were higher than in SCAD patients ((0.58 mmol/l
(0.4, 0.83) vs. 0.44 mmol/l (0.3, 0.63), P < 0.001, respect-
ively)) (Fig. 1c), and the difference still remained significant
after adjustment for age and gender (P < 0.001), suggesting
that FFAs content increased closely with the severity of
coronary artery lesions in CAD.
Meanwhile, the occurrence of ACS and STEMI in-
creased according to the FFAs quartiles (P value for
trend = 0.003, 0.001) (Fig. 1d, e). To explore the relation-
ship of FFAs and the prevalent ACS and STEMI, a binary
logistic regression analysis was performed. After adjusted
Table 1 Clinical characteristic of study population
Q1 (n = 223) Q2 (n = 218) Q3 (n = 228) Q4 (n = 223) P
FFAs (mmol/l) 0.27 (0.21, 0.32) 0.46 (0.42, 0.49) 0.65 (0.59, 0.72) 1.01 (0.88, 1.28) -
Demographics
Age (y) 63 ± 13 60 ± 10.4 60 ± 10.4 62 ± 12 0.021
Male (%) 65.5 67.9 70.6 66.8 NS
Risk factors
SBP (mmHg) 141 ± 24 133 ± 16 134 ± 21 124 ± 20 NS
DBP (mmHg) 82 ± 11 79 ± 11 82 ± 15 75 ± 11 NS
HR (bpm) 72 ± 7 74 ± 15 75 ± 8 74 ± 14 0.01
Smoking (%) 33.8 51.9 51.3 49.7 0.005
Hypertension (%) 67.7 69.3 65.4 57.4 0.043
Diabetes mellitus (%) 26.9 30.3 31.3 29.6 NS
Hyperlipidemia (%) 58.7 62.4 70.2 66.4 0.048
Laboratory parameter
TC (mmol/l) 4.04 ± 0.86 4.28 ± 1.04 4.78 ± 1.56 4.3 ± 0.88 <0.001
HDL-C (mmol/l) 1 ± 0.2 1.05 ± 0.2 0.99 ± 0.21 1 ± 0.2 NS
LDL-C (mmol/l) 2.5 ± 0.92 2.73 ± 0.83 2.93 ± 0.8 2.75 ± 0.7 <0.001
Lp (a) (mg/l) 131 (67, 246) 78 (37, 312) 125 (61, 202) 136 (56, 209) NS
TG (mmol/l) 1.63 ± 0.92 1.96 ± 1.37 2.35 ± 1.45 2.01 ± 1.6 <0.001
FBG (mmol/l) 5.96 ± 1.7 6.3 ± 2.6 7 ± 2.7 6.5 ± 3.3 <0.001
WBC (×109) 7.5 ± 3.7 6.9 ± 2.2 8.1 ± 3.1 9.24 ± 3.2 <0.001
cTnT(ng/ml) 0.02 (0.003, 0.49) 0.07 (0.007, 2.84) 0.28 (0.01, 6.65) 1.72 (0.05, 15.1) <0.001
hs-CRP (mg/l) 2.64 (0.58, 6.2) 2.42 (1.43, 3.83) 3.4 (1.16, 9.18) 2.43 (0.94, 11.7) <0.001
CK-MB (U/l) 13 (8.5, 18.5) 13 (9, 26) 18 (11, 49) 31 (12, 102.8) <0.001
eGFR (ml/min/1.73 m2) 93.4 ± 28.9 95.3 ± 20.2 98.2 ± 19.8 96.8 ± 30.8 NS
Angiographic analysis
Number of vessel 2.2 ± 0.6 2.13 ± 0.9 2.24 ± 0.74 1.97 ± 0.86 NS
Maximal stenosis (%) 78.3 ± 16.8 81.2 ± 20 83.3 ± 18 84.6 ± 19.1 <0.001
Gensini score 22.9 ± 18 29.9 ± 28 37.9 ± 30 43.7 ± 41 0.001
Final diagnosis
ACS n (%) 72 (8.1) 103 (11.5) 135 (15.1) 176 (19.7) <0.001
STEMI n(%) 11 (1.2) 31 (3.5) 60 (6.7) 92 (10.3) <0.001
Immediate therapy
β-Blocker n (%) 43 (19.2) 43 (19.8) 39 (17.1) 36 (16.3) NS
Aspirin n (%) 215 (96.3) 209 (95.7) 207 (91) 211 (94.5) NS
Stent implantation n (%) 60 (27.1) 62 (28.2) 68 (29.7) 70 (31.4) NS
Data were expressed as the mean ± SD, median (25th-75th percentile) or %.
Q = quartile, SBP systolic blood pressure, DBP diastolic blood pressure, HR heart rate
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for traditional cardiovascular risk factors including age,
SBP, DBP, smoking, history of hypertension, diabetes mel-
litus and hyperlipidemia, the FFAs levels remained posi-
tively associated with prevalent ACS and STEMI ((for the
occurrence of ACS, OR(95 % CI) = 9.956(5.21, 19.023),
P < 0.001; for the occurrence of STEMI, OR(95 % CI) =
8.428(4.619, 15.376), P < 0.001)) (Tables 2 and 3).
To further explore whether the FFAs levels could re-
flect the severity of ischemia and necrosis focus in ACS
patients, we performed Spearman’s correlation analysis.
It showed that FFA level was positively correlated with
Gensini score and maximal stenosis (r = 0.224, P < 0.001
and r = 0.224, P < 0.001) and remained significant after
adjustment for age and gender (P = 0.001 and P = 0.003).
The occurrence of a higher Gensini score with more than
40 increased according to the FFAs quartiles (P value for
trend < 0.001) (Fig. 1f), after adjusted for traditional car-
diovascular risk factors including age, SBP, DBP, smoking,
history of hypertension, diabetes mellitus and hyperlipid-
emia, the FFAs levels remained a risk factor for a higher
Gensini score with more than 40 ((OR(95 % CI) = 3.741
(1.826, 7.664), P < 0.001)) (Table 4). Correlations of FFAs
content with the infarct size in ACS patients, estimated by
CK-MB and cTnT were performed, showing that FFA
Fig. 1 Distributions of FFAs among CAD patients (a, b, c) and prevalence of ACS, STEMI and Gensini score more than 40 based on the FFAs
quartiles (d, e, f). Asterisks (*) represent a P-value <0.05. Q = quartile.
Table 2 Association of FFAs levels and quartiles with prevalent
ACS
Unadjusted Adjusted
OR (95 % CI) P OR (95 % CI) P
FFAs 8.727 (5.331, 14.286) <0.001 9.956 (5.21, 19.023) <0.001
FFAs quartile
Q1 1 1 -
Q2 1.833 (1.248, 2.693) 0.002 2.003 (1.201, 3.339) 0.008
Q3 1.811 (1.491, 2.199) <0.001 2.081 (1.592, 2.72) <0.001
Q4 1.988 (1.724, 2.292) <0.001 2.189 (1.794, 2.671) <0.001
Binary logistic regression analyses were performed. The adjusting confounders
included age, gender, SBP, DBP, smoking, history of hypertension, diabetes
mellitus and hyperlipidemia.
Q = quartile
Table 3 Association of FFAs levels and quartiles with prevalent
STEMI
Unadjusted Adjusted
OR (95 % CI) P OR (95 % CI) P
FFAs 6.634 (4.269, 10.31) <0.001 8.428 (4.619, 15.376) <0.001
FFAs quartile
Q1 1 1 -
Q2 3.569 (1.709, 7.453) <0.001 5.301 (1.702, 16.509) 0.004
Q3 2.736 (1.927, 3.885) <0.001 3.53 (2.02, 6.169) <0.001
Q4 2.419 (1.923, 3.042) <0.001 3.083 (2.143, 4.436) <0.001
Binary logistic regression analyses were performed. The adjusting confounders
included age, gender, SBP, DBP, smoking, history of hypertension, diabetes
mellitus and hyperlipidemia.
Q = quartile
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levels had positively weak correlations with infarct size
(r = 0.09, P < 0.001 and r = 0.022, P < 0.001).
Interaction between WBC, hs-CRP and FFAs
We constructed the multivariate linear regression analysis
to elucidate the association of FFAs with inflammation pa-
rameters, after adjusting for traditional cardiovascular risk
factors including age, SBP, DBP, smoking, history of hyper-
tension, diabetes mellitus and hyperlipidemia, which
showed after natural logarithm transformation that FFAs
were associated with hs-CRP (β = 0.003, p = 0.048) and
WBC (β = 0.042, p = 0.008), respectively.
The whole study population were divided into four
groups according to the FFAs quartiles and each group
was sectionalized into 2 subgroups according to their
high/low levels of WBC (≤10×109, >10×109) or hs-CRP
(≤3.0 mg/l, >3.0 mg/l) respectively [15]. As shown in
Fig. 2a, among all FFAs quartile groups, patients with
hs-CRP more than 3.0 mg/l were more susceptible to
Table 4 Association of FFAs levels and quartiles with Gensini
score more than 40
Unadjusted Adjusted
OR (95 % CI) P OR (95 % CI) P
FFAs 2.379 (1.393, 4.062) <0.001 3.74 (1.826, 7.664) <0.001
FFAs quartile
Q1 1 1 -
Q2 2.538 (1.094, 5.889) 0.03 1.934 (0.688, 5.435) NS
Q3 2.013 (1.358, 2.984) <0.001 1.68 (1.029, 2.743) 0.038
Q4 1.704 (1.308, 2.22) <0.001 1.605 (1.157, 2.223) 0.005
Binary logistic regression analyses were performed. The adjusting confounders
included age, gender, SBP, DBP, smoking, history of hypertension, diabetes
mellitus and hyperlipidemia.
Q = quartile
Fig. 2 Interaction between WBC counts, hs-CRP and FFAs levels in ACS (a, d, g), STEMI (b, e, h), Gensini Score (c, f, i). Asterisks (*) showed significant
difference in high/low hs-CRP and WBC levels by χ2 analysis. Pound key(#) represented significant difference in the comparison of interaction to non-
interaction between FFAs and hs-CRP. Joint mark (&) showed significant difference in the comparison of interaction to non-interaction between FFAs
and WBC counts. Q = quartile.
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ACS, compared to patients with hs-CRP less than
3.0 mg/l (P <0.05); the trend for ACS occurrence in both
high and low hs-CRP groups was significantly elevated
with the distribution of higher FFA level (P value for
trend < 0.05) (Additional file 1: Figure S1A). The occur-
rence of STEMI was elevated with higher hs-CRP, except
in the lowest FFAs quartile Q1 group (P < 0.05) (Fig. 2b);
a similar trend was observed in STEMI susceptibility
and FFAs level in both high and low hs-CRP groups
(P value for trend < 0.05) (Additional file 1: Figure S1B).
Meanwhile, higher hs-CRP level was associated with a
higher Gensini score in the FFAs quartile Q2 group
(P < 0.05) (Fig. 2c); the percentage of Gensini score
for more than 40 dramatically increased according to
FFAs quartiles in both high and lowe hs-CRP groups
(P value for trend <0.001) (Additional file 1: Figure S1C).
The similar trendsexist in WBC counts and ACS sus-
ceptibility (Fig. 2d, Additional file 1: Figure S1D), WBC
counts and STEMI susceptibility (Fig. 2e, Additional file 1:
Figure S1E), WBC counts and higher Gensini score (Fig. 2f,
Additional file 1: Figure S1 F), respectively.
The trend of ACS occurrence, STEMI attack and
higher Gensini score with higher FFAs in high hs-CRP
and WBC levels versus low hs-CRP and WBC levels
were suggestive of an interaction between hs-CRP, WBC
counts and FFAs in relation to the progress of myocar-
dial ischemia. After performed by logistic regression ana-
lysis, we found a multiplicative interaction between hs-
CRP, WBC and FFAs in ACS and STEMI susceptibility
and a higher Gensini score ((in relation to ACS suscepti-
bility, FFAs*hs-CRP, OR(95 % CI) = 1.029(1.016, 1.043),
P < 0.001, FFAs*WBC, OR(95 % CI) = 1.357(1.281, 1.438),
P < 0.001; in relation to STEMI susceptibility, FFAs*hs-
CRP, OR(95 % CI) = 1.016(1.008, 1.024), FFAs*WBC,
OR(95 % CI) = 1.246(1.194, 1.3), P < 0.001; in relation to a
higher Gensini score, FFAs*hs-CRP, OR(95 % CI) =
1.033(1.013, 1.054), P = 0.001, FFAs*WBC, OR(95 % CI) =
1.065(1.02, 1.112), P = 0.004)) (Fig. 2g, h, i), which suggests
that FFAs influence the progress of ischemia involved by
inflammation processes.
Discussion
The major findings of our study confirmed that FFAs
level might serve as a predictor of the severity of myo-
cardial ischemia during the subacute onset of ACS
attack. First and foremost, FFAs levels were higher in
the ACS patients than the SCAD population, especially
in STEMI patients. Second, the FFAs increased with the
severity of necrosis and ischemia, such as cTnT and
Gensini score. Moreover, we observed an association be-
tween WBC counts, hs-CRP and FFAs levels in incident
ACS and higher Gensini score, which implied a possible
interaction between FFAs and inflammation processes
influenced the severity of ischemia.
According to the previous studies, elevated FFAs levels
in AMI are associated with increased lipolytic activity,
owing to an immediate increase of catecholamine with
the activated sympathetic nervous system [16]. Although
increasing evidence has shown that an elevation of FFAs
level occurs after the onset of AMI and that higher FFAs
are associated with a greater incidence of major cardio-
vascular events [17], no study has resolved the principal
mystery whether FFAs directly trigger serious cardiovas-
cular disease or only predict cardiometabolic dysfunction
[18]. There are several mechanisms illustrating high
FFAs concentration may be toxic in acute ischemic myo-
cardium, such as mitochondrial uncoupling, activation
of lipids in mitochondria, inhibition of β-oxidation,
inhibition of the Na+-K+-ATPase pump leading to high
intracellular sodium and calcium, or reduction of GLU-4
causing reduced insulin-stimulated glucose transport
[19]. Therefore, it is a top priority to monitor and reduce
concentrations of FFAs in the post phase of ACS [20].
Moreover, we found hs-CRP, WBC and FFAs had a
multiple effect in relation to ACS susceptibility and severe
myocardial ischemia (Fig. 2), which implied a possible
mechanism relating FFAs together with inflammatory
factors influenced the progress of ischemia. Inflammatory
cytokines such as IL-6 and TNF-α were added to isolated
adipocytes, resulting in increased lipolysis and FFAs levels
in several in-vivo and in-vitro studies [21, 22], also,
elevated circulating FFA levels led to endothelial dysfunc-
tion in-vivo via activation of PKC-mediated inflammatory
pathways and excess generation of oxidants [23, 24],
which would partially explain the clinically demonstrated
proarrhythmogenic potential of FFAs. Further investiga-
tions in the underlying mechanisms for the joint effect of
elevated FFA and inflammatory factors on myocardial
ischemia are apparently warranted.
Interestingly, preexisting hypertension had been diag-
nosed in SCAD, ACS and STEMI patients with the
prevalence of 70.5 %, 60.2 % and 48.1 %, respectively
and that decreased ratio of hypertension was associated
with higher occurrence of ACS and STEMI (Additional
file 2). The role of hypertension history in the prevalence
of ACS was difficult to explain. A large observational
study showed that patients with preexisting hypertension
had a more favorable in-hospital outcome [25]. Despite
with a higher risk, hypertensive patients was para-
doxically associated with a more favorable in-hospital
diagnosis. Underlied the mystery, awareness and treat-
ment of hypertension with potentially cardio-protective
antihypertensive drugs might function as a ‘protective’
effect [25].
Conclusions
FFAs levels may be indicative of the severity of myocar-
dial ischemia at subacute ACS onset and the combined
Ma et al. BMC Cardiovascular Disorders  (2016) 16:29 Page 6 of 7
effect of FFAs and activated inflammation might play a
role in myocardial ischemia of ACS.
Additional files
Additional file 1: Figure S1. The occurrence of ACS, STEMI and
percentage of Gensini score more than 40 according to high/low WBC
and hs-CRP levels. Asterisks (*) showed significant difference among the
FFAs quartiles by χ2 analysis. Q=quartile. (TIF 97015 kb)
Additional file 2: Table S1. The results of χ2 analysis for occurrence of
hypertension in study population (DOCX 13 kb)
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